AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Biodexa Activates First Clinical Site for Phase 3 Serenta Trial in FAP Patients.
ByAinvest
Wednesday, Jun 25, 2025 8:40 am ET1min read
Biodexa Pharmaceuticals PLC has activated the first clinical study site for its Serenta trial in patients with familial adenomatous polyposis (FAP). The trial, now enrolling, aims to evaluate the safety and efficacy of eRapa in individuals diagnosed with FAP. The first site, in the US, is open and actively screening eligible participants. This represents a significant milestone in developing a potential new treatment option for FAP.
Biodexa Pharmaceuticals PLC (BDRX) has activated the first clinical study site for its Serenta trial in patients with familial adenomatous polyposis (FAP). The trial, now enrolling participants, aims to evaluate the safety and efficacy of eRapa in individuals diagnosed with FAP. The first site, located in the US, is open and actively screening eligible participants.The Serenta trial (NCT06950385) is a randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of eRapa in FAP patients. The trial is supported by significant funding and regulatory approvals, including a $20 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT), Fast Track Designation, and a positive Type C Meeting.
Biodexa has also launched a dedicated website, serentatrial.com, to provide resources and updates on the trial. The activation of the first clinical study site marks a significant milestone in the development of a potential new treatment option for FAP, a rare, inherited disorder characterized by the development of hundreds to thousands of colorectal polyps and a near-100% lifetime risk of colorectal cancer if left untreated.
References:
[1] https://www.globenewswire.com/news-release/2025/06/25/3105070/0/en/Biodexa-Announces-Activation-of-First-Clinical-Study-Site-for-Phase-3-Serenta-Trial-in-Familial-Adenomatous-Polyposis-FAP.html
[2] https://www.stocktitan.net/news/BDRX/biodexa-announces-activation-of-first-clinical-study-site-for-phase-56fnenxpb2a2.html
[3] https://www.gurufocus.com/news/2939156/biodexa-unveils-serenta-as-the-name-of-its-upcoming-phase-3-study-in-familial-adenomatous-polyposis-fap-bdrx-stock-news
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc's editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet